Storia in 2 fonti

Galderma gets CRL for anti-wrinkle drug; Kimball buys CDMO for $103M

Biopharma manufacturing briefs: Galderma's CRL for relabotulinumtoxinA, Kimball's $103M CDMO buy, and more.

Raccontata da

fiercepharma.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Galderma gets CRL for anti-wrinkle drug; Kimball buys CDMO for $103M

Biopharma manufacturing briefs: Galderma's CRL for relabotulinumtoxinA, Kimball's $103M CDMO buy, and more.

originale

fiercepharma.com1 mese fa

Kimball lays out $103M to bolster life sciences CDMO footprint across Europe, India

On a quest to bolster its life-sci contracting bona fides, self-described “multifaceted manufacturer” Kimball Electronics is going down the path of M&A. | On a quest to bolster its life-sci contracting bona fides,…

Leggi questa versione → originale

Timeline cronologica

mercoledì 1 luglio 2026·fiercepharma.com
Kimball lays out $103M to bolster life sciences CDMO footprint across Europe, India
On a quest to bolster its life-sci contracting bona fides, self-described “multifaceted manufacturer” Kimball Electronics is going down the path of M&A. | On a quest to bolster…
giovedì 2 luglio 2026·endpoints.news
Galderma gets CRL for anti-wrinkle drug; Kimball buys CDMO for $103M
Biopharma manufacturing briefs: Galderma's CRL for relabotulinumtoxinA, Kimball's $103M CDMO buy, and more.